1(904)362-3629 [email protected]

Elixinol to Purchase 25% Stake in Pet Releaf Brand CBD Products

by Chris Husong – We’re excited to announce that we have acquired a 25 percent stake in Altmeds LLC, which is the visionary producer of the market-leading Pet Releaf CBD pet line. Pet Releaf products consist of hemp-derived CBD supplements and products for pets. These include products such as CBD oil pet treats and CBD oil for dogs. Pet Releaf products accounted for over half of pet CBD sales last year, commanding 65 percent of the pet CBD market in 2018.

Two Companies, One Vision

Stephen Smith, President and Co-Founder of Pet Releaf, said, “Pet Releaf and Elixinol share the same values in sourcing and end-product superiority.”

He continued to state the positives of the partnership by saying, “The partnership of two best-in-class companies means Pet Releaf will gain additional working capital to be able to expand our reputation for innovation, and increase our scientific and international expertise while still maintaining our ‘from seed to sale from plant to pet™’ approach.”

Our History and Our Future

Elixinol has worked with the founders of Pet Releaf for many years, combining our shared expertise of scientific principles, farming, and production ideas. We’ve also been working closely together to further develop strategies for our products moving forward.

Pet Releaf products use a hemp extract sourced from a USDA Organic certified hemp strain, grown and developed solely by us at Elixinol for use in Pet Releaf products. Together, we can effectively leverage seed to sale scalability to further optimize our production efficiencies by focusing on our proprietary, in-house processing technologies.

Altmeds LLC’s Pet Releaf line of products, notably their CBD pet treats, is currently sold in over 4,000 independent pet stores throughout the USA as well as multiple international markets. Pet Releaf’s hemp derived CBD pet products consist of topicals, edibles, and oils aimed at giving our pets access to the same healthy supplements that we use to take care of ourselves.

Our new stake in Pet Releaf will allow us to strengthen an already strong relationship with an influential private label partner, as well as allowing us to secure a profitable investment in the quickly-expanding hemp-derived CBD pet products market.

Growing a Brand We Believe In

Pet Releaf intends to utilize the majority of our investment to fund working capital and to prepare the business for projected continued growth in the market. They will be introducing new product lines, making strategic hires, and utilizing the increased capacity of their new state-of-the-art, 25,000-foot production facility.

We don’t just have a financial investment in Pet Releaf; we have a personal investment. We’re aware that pets play a significant role in our lives and in the lives of many of our customers. Our stake in Pet Releaf helps them to assure customers that the exact same company values and ethics are being applied to the products that our customers purchase for their pets as those that they purchase for themselves.

More About Pet Releaf™:

Pet Releaf is based in Denver Colorado and is an employee-owned company. The company was co-founded by Steve and Alina Smith in 2015 to ensure that truly healthy products were available for pets and that those products were produced with ethics important to the founds, specifically honesty and integrity.

Steve and Alina Smith began the company partially as a reaction to their own dog, Mattie, experiencing negative reactions to the strong medications prescribed to her for a severe condition. This led to the creation of Edibites™, a CBD treat for dogs, as well as Organic CBD hemp oil products for dogs and cats.

Pet Releaf’s products are made in small batches and independently tested by third-party labs. For more information about Pet Releaf, please visit www.petreleaf.com or connect with Pet Releaf on Facebook, Twitter, Pinterest, and Instagram.

The post Elixinol to Purchase 25% Stake in Pet Releaf Brand CBD Products appeared first on Elixinol.